<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Formulary Drug Review: Ocrelizumab

descriptionPublicationkeyboard_double_arrow_right Article 17 Sep 2017 United States English Publisher:SAGE PublicationsJournal:Hospital Pharmacy, volume 52, pages 599-606 (issn: 0018-5787, eissn: 1945-1253,

Authors: Ali, Zaynah K; Baker, Danial E;

doi: 10.1177/0018578717731733

pmid: 29276296

pmc: PMC5735732

Formulary Drug Review: Ocrelizumab

- Summary
- Subjects
- Related research
  (40)
- Metrics

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Country

United States

Related Organizations

Washington State University
United States

Keywords

Formulary Drug Reviews

40 Research products, page 1 of 4

Sugammadex
2016IsAmongTopNSimilarDocuments
Formulary Drug Review: Edaravone
2017IsAmongTopNSimilarDocuments
Fostemsavir
2021IsAmongTopNSimilarDocuments
Risankizumab
2019IsAmongTopNSimilarDocuments
Tirzepatide
2022IsAmongTopNSimilarDocuments
Formulary Drug Reviews: Brexanolone Injection
2019IsAmongTopNSimilarDocuments
Formulary Drug Reviews: Terlipressin
2023IsAmongTopNSimilarDocuments
Formulary Drug Review: Odevixibat
2022IsAmongTopNSimilarDocuments
Daclizumab
2016IsAmongTopNSimilarDocuments
Patiromer
2016IsAmongTopNSimilarDocuments

chevron_left
1
2
3
4
chevron_right

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	3
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average